Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti-Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705).

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic v v i Flemingovo nám 2 CZ 16610 Prague 6 Czech Republic

Zobrazit více v PubMed

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl‐Jensen V, Warren TK, Weidmann M, Nichol ST. Virus nomenclature below the species level: A standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol 2013;158:301–311. PubMed PMC

Bray M. Defense against filoviruses used as biological weapons. Antiviral Res 2003;57:53–60. PubMed

Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010;155:2083–2103. PubMed PMC

Anonymous. Ebola haemorrhagic fever in Sudan, 1976 . Report of a WHO/International Study Team. Bull World Health Organ 1978;56:247–270. PubMed PMC

Anonymous. Ebola haemorrhagic fever in Zaire, 1976 . Report of an International Commission. Bull World Health Organ 1978;56:271–293. PubMed PMC

World Health Organization . Ebola virus disease Fact sheet No. 103. September 2014. http://www.who.int/mediacentre/factsheets/fs103/en/

Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol 2014;95:1619–1624. PubMed

http://www.who.int/csr/disease/ebola/situation-reports/en/

Kucharski AJ, Edmunds WJ. Case fatality rate for Ebola virus disease in west Africa. Lancet 2014;384:1260. PubMed

Geisbert TW, Jahrling PB. Exotic emerging viral diseases: Progress and challenges. Nat Med 2004;10:S110–S121. PubMed

Nkoghe D, Leroy EM, Toung‐Mve M, Gonzalez JP. Cutaneous manifestations of filovirus infections. Int J Dermatol 2012;51:1037–1043. PubMed

West TE, von Saint André‐vonArnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc 2014;11:1341–1350. PubMed

Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377:849–862. PubMed PMC

Hoenen T, Groseth A, Callison J, Falzarano D, Feldmann H. Ebola virus: Unraveling pathogenesis to combat a deadly disease. Trends Mol Med 2006;12:206–215. PubMed

Leyssen P, De Clercq E, Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 2008;78:9–25. PubMed PMC

Bray M, Paragas J. Experimental therapy of filovirus infections. Antiviral Res 2002;54:1–17. PubMed

De Clercq E. A cutting‐edge view on the current state of antiviral drug development. Med Res Rev 2013;33:1249–1277. PubMed

Wong G, Qiu X, Olinger GG, Kobinger GP. Post‐exposure therapy of filovirus infections. Trends Microbiol 2014;22:456–463. PubMed

Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, Olinger GG. Potential vaccines and post‐exposure treatments for filovirus infections. Viruses 2012;4:1619–1650. PubMed PMC

Li H, Ying T, Yu F, Lu L, Jiang S. Development of therapeutics for treatment of Ebola virus infection. Microbes Infect 2015;17:109–117. PubMed

Picazo E, Giordanetto F. Small molecule inhibitors of ebola virus infections. Drug Discov Today 2015;20;277–286. PubMed

De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol 2015;93:1–10. PubMed PMC

Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2015;49:196–206. PubMed

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther‐Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014;514:47–53. PubMed PMC

Bradfute SB, Dye JM, Bavari S. Filovirus vaccines. Hum Vaccin 2011;7:701–711. PubMed PMC

Hoenen T, Groseth A, Feldmann H. Current Ebola vaccines. Expert Opin Biol Ther 2012;12:859–872. PubMed PMC

Marzi A, Feldmann H. Ebola virus vaccines: An overview of current approaches. Expert Rev Vaccines 2014;13:521–531. PubMed PMC

Graci JD, Cameron CE. Mechanism of action of ribavirin against distinct viruses. Rev Med Virol 2006;16:37–48. PubMed PMC

Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad‐spectrum antiviral drug. Rev Infect Dis 1989;11:S750–S761. PubMed

Huggins JW, Zhang Z, Monath TI. Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S‐adenosylhomocysteine hydrolase inhibitors. Antiviral Res 1995;1:S122.

Huggins J, Zhang Z‐X, Bray M. Antiviral drug therapy of filovirus infections: S‐adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999;179:S240–S247. PubMed

Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S‐adenosyl‐L‐homocysteine hydrolase inhibitor. Antiviral Res 2000;45:135–147. PubMed

Montgomery JA, Clayton SJ, Thomas HJ, Shannon WM, Arnett G, Bodner AJ, Kion I‐K, Cantoni GL, Chiang PK. Carbocyclic analogue of 3‐deazaadenosine: A novel antiviral agent using S‐adenosylhomocysteine hydrolase as a pharmacological target. J Med Chem 1982;25:626–629. PubMed

De Clercq E. S‐adenosylhomocysteine hydrolase inhibitors as broad‐spectrum antiviral agents. Biochem Pharmacol 1987;36:2567–2575. PubMed

De Clercq E. Carbocyclic adenosine analogues as S‐adenosylhomocysteine hydrolase inhibitors and antiviral agents: Recent advances. Nucleosides Nucleotides 1998;17:625–634. PubMed

De Clercq E. John Montgomery's Legacy: Carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad‐spectrum antiviral activity. Nucleosides Nucleotides Nucleic Acids 2005;24:1395–1415. PubMed

Bray M, Raymond JL, Geisbert T, Baker RO. 3‐Deazaneplanocin A induces massively increased interferon‐α production in Ebola virus‐infected mice. Antiviral Res 2002;55:151–159. PubMed

De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004;2:704–720. PubMed PMC

Ye W, Schneller SW. The enantiomers of the 1’,6’‐isomer of neplanocin A: Synthesis and antiviral properties. Bioorg Med Chem 2014;22:5315–5319. PubMed

St. Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA, Korshun VA, Tyrrell DLJ, Schang LM. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 2010;107:17339–17344. PubMed PMC

Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. Protection against filovirus diseases by a novel broad‐spectrum nucleoside analogue BCX4430. Nature 2014;508:402–405. PubMed PMC

Kicska GA, Long L, Hörig H, Fairchild C, Tyler PC, Furneaux RH, Schramm VL, Kaufman HL. Immucillin H, a powerful transition‐state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci USA 2001;98:4593–4598. PubMed PMC

Schramm V. Transition states, analogues, and drug development. ACS Chem Biol 2013;8:71−81. PubMed PMC

Julander JG, Bantia S, Taubenheim BR, Minning DM, Kotian P, Morrey JD, Smee DF, Sheridan WP, Babub YS. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob Agents Chemother 2014;58:6607−6614. PubMed PMC

http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=887581

Florescu DF, Keck MA. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti‐infect Ther 2014;12:1171–1178. PubMed

Tollefson AE, Spencer JF, Ying B, Buller RML, Wold WSM, Toth K. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antivir Res 2014;112:38–46. PubMed

Sandkovsky U, Vargas L, Florescu DF. Adenovirus: Current epidemiology and emerging approaches to prevention and treatment. Curr Infect Dis Rep 2014;16:416–423. PubMed

Olson VA, Smith SK, Foster S, Li Y, Randall Lanier E, Gates I, Trost LC, Damona IK. In vitro efficacy of Brincidofovir against Variola virus. Antimicrob Agents Chemother 2014;58:5570–5571. PubMed PMC

Griffiths P, Lumley S. Cytomegalovirus. Curr Opin Infect Dis 2014;27:554–559. PubMed

De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261–272. PubMed

De Clercq E, Holý A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat Rev Drug Discov 2005;4:928–940. PubMed

Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RML, Painter GR, Wold WSM. Hexadecyloxypropyl‐cidofovir, CMX001, prevents adenovirus‐induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008;105:7293–7297. PubMed PMC

Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja‐Marin H, Boeckh M. CMX001 to prevent cytomegalovirus disease in hematopoietic‐cell transplantation. New Engl J Med 2013;369:1227–1236. PubMed

Chimerix . Chimerix announces emergency investigational new drug applications for brincidofovir authorized by FDA for patients with Ebola virus disease. Available at http://ir.chimerix.com/releasedetail.cfm?releaseid=874647 (accessed October 7, 2014).

Günther S, Asper M, Röser C, Luna LKS, Drosten C, Becker‐Ziaja B, Borowski P, Chen, H‐M , Hosmane RS. Application of real‐time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res 2004;63:209–215. PubMed PMC

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T‐705 (favipiravir) and related compounds: Novel broad‐spectrum inhibitors of RNA viral infections. Antiviral Res 2009:82:95–102. PubMed PMC

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T‐705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446–454. PubMed PMC

Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti‐influenza virus compound T‐705. Antimicrob Agents Chemother 2002;46:977–981. PubMed PMC

Furuta Y, Takahashi K, Kuno‐Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T‐705 against influenza virus. Antimicrob Agents Chemother 2005;49:981–986. PubMed PMC

Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post‐exposure efficacy of oral T‐705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014;104:153–155. PubMed

Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz‐Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T‐705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17–21. PubMed

Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. The ambiguous basepairing and high substrate efficiency of T‐705 (favipiravir) ribofuranosyl 5′‐triphosphate towards influenza A virus polymerase. PLoS One 2013;8:e68347. PubMed PMC

Baranovich T, Wong S‐S, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. T‐705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013;87:3741–3751. PubMed PMC

Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1. Nature 2011;477:340–343. PubMed PMC

Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection. Nature 2011;477:344–348. PubMed PMC

Wolf MC, Freiberg AN, Zhang T, Akyol‐Ataman Z, Grock A, Hong PW, Li J, Watsona NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal E, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. A broad‐spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010;107:3157–3162. PubMed PMC

Vigant F, Lee J, Hollmann A, Tanner LB, Akyol‐Ataman Z, Yun T, Shui G, Aguilar HC, Zhang D, Meriwether D, Roman‐Sosa G, Robinson LR, Juelich TL, Buczkowski H, Chou S, Castanho MARB, Wolf MC, Smith JK, Banyard A, Kielian M, Reddy S, Wenk MR, Selke M, Santos NC, Freiberg AN, Jung ME, Lee B. A mechanistic paradigm for broad‐spectrum antivirals that target virus‐cell fusion. PLoS Pathog 2013;9:e1003297. PubMed PMC

Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier‐Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL. Identification of a small‐molecule entry inhibitor for filoviruses. J Virol 2011;85:3106–3119. PubMed PMC

Johnson JC, Martinez O, Honko AN, Hensley LE, Olinger GG, Basler CF. Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res 2014;107:102–109. PubMed PMC

Yermolina MV, Wang J, Caffrey M, Rong LL, Wardrop DJ. Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem 2011;54:765–781. PubMed PMC

Yonezawa A, Cavrois M, Greene WC. Studies of ebola virus glycoprotein‐mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: Involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol 2005;79:918–926. PubMed PMC

Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS. Identification of a broad‐spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high‐throughput screening assay. J Virol 2014;88:4353–4365. PubMed PMC

Nierengarten I, Nierengarten J‐F. Fullerene sugar balls: A new class of biologically active fullerene derivatives. Chem Asian J 2014;9:1436–1444. PubMed

Luczkowiak J, Muñoz A, Sánchez‐Navarro M, Ribeiro‐Viana R, Ginieis A, Illescas BM, Martín N, Delgado R, Rojo J. Glycofullerenes inhibit viral infection. Biomacromolecules 2013;14:431–437. PubMed

Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks DD, Davey RA, Kolokoltsov AA, Jr Carrion R, , Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ. A systematic screen of FDA‐approved drugs for inhibitors of biological threat agents. PLoS One 2013;8:e60579. PubMed PMC

Kouznetsova J, Sun W, Martínez‐Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, García‐Sastre A. Identification of 53 compounds that block Ebola virus‐like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 2014;3:e84. PubMed PMC

Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N, Perovic VR, Cavanaugh DP, Branch DR. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research 2015;4;34. PubMed PMC

Adams CE, Rathbone J, Thornley B, Clarke M, Borrill J, Wahlbeck K, Awad AG. Chlorpromazine for schizophrenia: A Cochrane systematic review of 50 years of randomised controlled trials. BMC Med 2005;3:15. PubMed PMC

Bhattacharyya S, Warfield KL, Ruthel G, Bavari S, Aman MJ, Hope TJ. Ebola virus uses clathrin mediated endocytosis as an entry pathway. Virol 2010; 401:18–28. PubMed PMC

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Evans DeWald L, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG. FDA‐approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013;5:190ra79. PubMed PMC

Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM. Multiple cationic amphiphiles induce a Niemann‐Pick C phenotype and inhibit ebola virus entry and infection. PLoS One 2013;8:e56265. PubMed PMC

Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FWR, David S, Manns MP, Ciesek S, von Hahn T. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014;69:2123–2131. PubMed PMC

Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160:1741–1748. PubMed

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M., Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S. Antiviral activity of a small‐molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010;54:2152–2159. PubMed PMC

Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang O, Porter K, Goldblatt M, Bavari S. Development of a broad‐spectrum antiviral with activity against Ebola virus. Antivir Res 2009;83:245–251. PubMed

Lee SMY, Yen HL. Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infection. Antivir Res 2012;96:391–404. PubMed PMC

Opsenica I, Burnett JC, Gussio R, Opsenica D, Todorovic N, Lanteri CA, Sciotti RJ, Gettayacamin M, Basilico N, Taramelli D, Nuss JE, Wanner L, Panchal RG, Šolaja BA, Bavari S. A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin serotype a light chain, p. Falciparum malaria, and the ebola filovirus. J Med Chem 2011;54:1157–1169. PubMed PMC

Selaković Ž, Opsenica D, Eaton B, Retterer C, Bavari S, Burnett JC, Šolaja BA, Panchal RG. A limited structural modification results in a significantly more efficacious diazachrysene‐based filovirus inhibitor. Viruses 2012;4:1279–1288. PubMed PMC

Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher‐Hennings J, Olinger GG, Goldblatt M. FGI‐104: A broad‐spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009;1:87–98. PubMed PMC

Harty RN. No exit: Targeting the budding process to inhibit filovirus replication. Antiviral Res 2009;81:189–197. PubMed PMC

Liu Y, Lee MS, Olson MA, Harty RN. Bimolecular complementation to visualize filovirus VP40‐host complexes in live mammalian cells: Toward the identification of budding inhibitors. Adv Virol 2011;341816. PubMed PMC

Kinch M, Goldblatt M. Methods of inhibiting viral infection. 2009, WO 2009/091435 A2.

Kesel AJ. Broad‐spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative. Eur J Med Chem 2011;46:1656–1664. PubMed

Kesel AJ, Huang Z, Murray MG, Prichard MN, Caboni L, Nevin DK, Fayne D, Lloyd DG, Detorio MA, Schinazi RF. Retinazone inhibits certain bloodborne human viruses including Ebola virus Zaire. Antivir Chem Chemother 2014;23:197–215. PubMed PMC

Chang J, Wang L, Ma D, Qu X, Guo H, Xu X, Mason PM, Bourne N, Moriarty R, Gu B, Guo JT, Block TM. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother 2009;53:1501–1508. PubMed PMC

Chang J, Schul W, Butters TD, Yip A, Liu B, Goh A, Lakshminarayana SB, Alonzi D, Reinkensmeier G, Pan X, Qu X, Weidner JM, Wang L, Yu W, Borune N, Kinch MA, Rayahin JE, Moriarty R, Xu X, Shi PY, Guo JT, Block TM. Combination of alpha‐glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res 2011;89:26–34. PubMed PMC

Chang J, Schul W, Yip A, Xu X, Guo JT, Block TM. Competitive inhibitor of cellular alpha‐glucosidases protects mice from lethal dengue virus infection. Antiviral Res 2011;92:369–371. PubMed PMC

Chang J, Warren TK, Zhao X, Gill T, Guo F, Wanga L, Comunale MA, Duc Y, Alonzi DS, Yu W, Ye H, Liu F, Guo J‐T, Mehta A, Cuconati A, Butters TD, Bavari S, Xu X, Block TM. Small molecule inhibitors of ER alpha‐glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res 2013;98:432–440. PubMed PMC

Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe GK. Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci USA 2009;106:411–416. PubMed PMC

Leung DW, Prins KC, Basler CF, Amarasinghe GK. Ebolavirus VP35 is a multifunctional virulence factor. Virulence 2010;1:526–531. PubMed PMC

Brown CS, Lee MS, Leung DW, Wang T, Xu W, Luthra P, Anantpadma M, Shabman RS, Melito LM, MacMillan KS, Borek DM, Otwinowski Z, Ramanan P, Stubbs AJ, Peterson DS, Binning JM, Tonelli M, Olson MA, Davey RA, Ready JM, Basler CF, Amarasinghe GK. In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol 2014;426:2045–2058. PubMed PMC

Ekins S, Freundlich JS, Coffee M. A common feature pharmacophore for FDA‐approved drugs inhibiting the Ebola virus. F1000Research 2014;3;277. PubMed PMC

Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S. Identification of an antioxidant small‐molecule with broad‐spectrum antiviral activity. Antiviral Res 2012;93:23–29. PubMed

Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN. Small‐molecule probes targeting the viral PPxY‐host Nedd4 interface blco egress of a broad range of RNA viruses. J Virol 2014;88:7294–7306. PubMed PMC

Lu J, Han Z, Liu Y, Liu W, Lee MS, Olson MA, Ruthel G, Freedmen BD, Harty RN. A host‐oriented inhibitor of Junin Argentine hemorrhagic fever virus egress. J Virol 2014;88:4736–4743. PubMed PMC

Dias N, Stein CA. Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 2002;1:347–355. PubMed

Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008;78:26–36. PubMed PMC

Jain ML, Bruice PY, Szabó IE, Bruice TC. Incorporation of positively charged linkages into DNA and RNA backbones: A novel strategy for antigene and antisense agents. Chem Rev 2012;112:1284–1309. PubMed

Sahin U, Karikó K, Türeci Ö. mRNA‐based therapeitics—Developing a new class of drugs. Nat Rev Drug Discov 2014;13:759–780. PubMed

Chan JH, Lim S, Wong WS. Antisense oligonucleotides: From design to therapeutic application. Clin Exp Pharmacol Physiol 2006;33:533–540. PubMed

Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S. Gene‐specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006;2:e1. PubMed PMC

Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, Iversen PL, Bavari S, Muhlberger E. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006;50:984–993. PubMed PMC

Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16:991–994. PubMed

Warren TK, Shurtleff AC, Bavari S. Advanced morpholino oligomers: A novel approach to antiviral therapy. Antiviral Res 2012;94:80–88. PubMed PMC

Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S. Discovery and early development of AVI‐7537 and AVI‐7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 2012;4:2806–2830. PubMed PMC

Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: Results of two single‐ascending‐dose studies. Antimicrob Agents Chemother 2014;58:6639–6647. PubMed PMC

Fowler T, Bamberg S, Möller P, Klenk H‐D, Meyer TF, Becker S, Rudel T. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005;86:1181–1188. PubMed

Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario‐Dicaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee ACH, Judge A, Jeffs LB, MacLachlan I. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193:1650–1657. PubMed PMC

Thi EP, Mire CE, Ursic‐Bedoya R, Geisbert JB, Lee ACH, Agans KN, Robbins M, Deer DJ, Fenton KA, MacLachlan I, Giesbert TW. Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid‐encapsulated siRNA. Sci Transl Med 2014;6:250ra116. PubMed PMC

Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B. Potent and persistent in vivo anti‐HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002–1007. PubMed

Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, MacLachlan I. Postexposure protection of non‐human primates against a lethal Ebola virus challenge with RNA interference: A proof‐of‐concept study. Lancet 2010;375:1896–905. PubMed PMC

Paragas J, Geisbert TW. Development of treatment strategies to combat Ebola and Marburg viruses. Expert Rev Anti Infect Ther 2006;4:67–76. PubMed

Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 2008;78:150–161. PubMed

Hoenen T, Groseth A, Callison J, Takada A, Feldmann H. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res 2013;99:207–213. PubMed PMC

Uebelhoer LS, Albariño CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, Towner JS. High‐throughput, luciferase‐based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res 2014;106:86–94. PubMed

Gowen BB, Holbrook MR. Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses. Antiviral Res 2008;78:79–90. PubMed

Bradfute SB, Warfield KL, Bray M. Mouse models for Filovirus infections. Viruses 2012;4:1477–1508. PubMed PMC

Nakayama E, Saijo M. Animal models for Ebola and Marburg virus infections. Front Microbiol 2013;4:267. PubMed PMC

Safronetz D, Geisbert TW, Feldmann H. Animal models for highly pathogenic emerging viruses. Curr Opin Virol 2013;3:205–209. PubMed PMC

Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and ebola viruses In: Knipe DM, Howley PM, Eds. Fields Virology, 6th ed Philadelphia: Lippincott, Williams and Wilkins; 2013. p 923–956.

Médecins Sans Frontiéres. http://www.msf.org/article/clinical-trial-potential-ebola-treatment-started-msf-clinic-guinea.